Research
Cellular
Semaglutide and tirzepatide resolve metabolic dysfunction-associated steatohepatitis (MASH) in 41% and 53% of patients, respectively, without worsening fibrosis after 52-72 weeks.
These medications can significantly improve liver health in adults with MASH.
StrongSupportsmedium confidence
Semaglutide and tirzepatide resolve metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis placebo-subtracted in 41% and 53% of patients, respectively, after 52-72 weeks.
Why this rating
Based on randomized controlled trials.
Source
Antiobesity medications in adult and pediatric obesity and metabolic dysfunction–associated steatotic liver disease
Natalie Rodríguez et al. · Pharmacological Reviews · 2025
DOI 10.1016/j.pharmr.2025.100058
reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →